Login to Your Account

Lux Targets 2013 Refiling for Voclosporin in Uveitis

By Jennifer Boggs
Managing Editor

Wednesday, August 8, 2012

Nearly two years after a complete response letter (CRL) delayed Lux Biosciences Inc.'s plans for oral voclosporin in noninfectious uveitis, the Jersey City, N.J.-based biotech completed patient enrollment in a new Phase III study aimed at addressing the FDA's request for additional clinical data.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription